The TruCulture system will be utilized for blood collection and culture.
Rules-Based Medicine has signed on as a collaborator on the Institut Pasteur research project called Milieu Interieur (or the environment within), which aims to understand the complexities of the human immune system. RBM’s TruCulture®, an in vitro model that reportedly preserves physiological cellular interactions, will be used in the research.
Milieu Interieur is funded through a LabEx grant from the French government. A federation of researchers and clinicians from Institut Pasteur, the French National Institute of Health and Medical Research (INSERM), and the National Centre for Scientific Research (CNRS) are integrating cutting-edge technologies from a number of scientific disciplines including immunology, genomics, molecular biology, and bioinformatics to establish the parameters that characterize the immune system of healthy individuals.
“Susceptibility to infections, severity of disease, and response to medical therapies and vaccines are highly variable from one individual to another,” points out Matthew Albert, director of the department of immunology, Institut Pasteur. “TruCulture is an ideal research tool that simplifies the sample collection and culturing process and will help to reveal the linkages between the genotypes and phenotypes that are responsible for immune system variability.”
The TruCulture system will be utilized for blood collection and culture. It is expected that at least 40,000 TruCulture tubes will be required to characterize the immune responses of the 1,000 participants. TruCulture is designed to capture immune cell activity while avoiding many of the variables often associated with sample collection and manipulation, according to RBM. An important advantage of this collection system is that cell stimulations are performed instantly, at the point of collection, which provides a more accurate snapshot of the subject’s immune response, the firm adds.
RBM entered an agreement on April 27 to be acquired by Myriad Genetics. The company offered $80 million, and the transaction is expected to be complete by May 31. Myriad Genetics will gain a marketed molecular diagnostic and eight new diagnostic candidates.